1. Articles in category: Low / Intermediate Risk

    1-4 of 4
    1. Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosis.

      Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosis.

      Jpn J Clin Oncol. 2016 Jul;46(7):661-6

      Authors: Iehara T, Yagyu S, Tsuchiya K, Kuwahara Y, Miyachi M, Tajiri T, Sugimoto T, Sawada T, Hosoi H

      Abstract BACKGROUND: It remains unclear whether a residual tumor mass following therapy influences the prognosis of neuroblastoma.

      Read Full Article
      Mentions: MIBG
    2. Simple test predicts childhood cancer relapse

      Simple test predicts childhood cancer relapse

      Researchers at Brunel University London and University College London have pinpointed a protein marker, which when absent, shows neuroblastoma is almost certain to recur. It means children with low-risk neuroblastoma, who don’t have the biomarker called PML, can be reclassified as at high risk of relapse and have chemotherapy earlier. A cheap simple test could accurately predict the recurrence of a childhood cancer.

      Read Full Article
    3. Current Management of Neonatal Neuroblastoma.

      "The epidemiology of neonatal (age less than 30 days) neuroblastoma contrasts greatly with patients older than 30 days. Owing to the unique potential for spontaneous regression of this tumor type, several groups have sought to reduce therapy given to neonates with neuroblastoma and use a watch-and-wait approach for many low-risk patients. Ongoing studies also seek to reduce therapy for some intermediate-risk patients in an attempt to lessen exposure to surgical intervention and cytotoxic chemotherapy. In this review, we discuss the epidemiology, clinical presentation, staging, and treatment for neonates with neuroblastoma."

      Read Full Article
      Mentions: Surgery
    4. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.

      Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.

      Clin Cancer Res. 2014 Sep 17;

      Authors: Oberthuer A, Juraeva D, Hero B, Volland R, Carolina S, Schmidt R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger RC, Ohira M, Nakagawara A, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Speleman F, Noguera R, Piqueras M, Benard J, Valent A, Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, Brors B, Fischer M ...

      Read Full Article
      Mentions: GPOH Diagnostics
    1-4 of 4
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles